Skip to main content

Table 4 Pronostic factors of overall survival (Cox model)

From: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

  Univariate analysis   Multivariate analysis  
  HR p HR p
Gleason score 4-6 1    
7 1.54 95% CI [0.91-2.60] 0.11
8-10 1.63 95% CI [0.98-2.72] 0.06
Nb CT line 1 1    
2 1.17 95% CI [0.86-1.60] 0.309
3 1.09 95% CI [0.59-2.03] 0.785
4 1.11 95% CI [0.52-2.39] 0.788
5 0.81 95% CI [0.11-5.82] 0.835
Sites of metastasis Bone or visceral alone vs Multiple 1 0.025 1 0.019
1.38   1.41
95% CI [1.04-1.83]   95% CI [1.05-1.88]
Previous hormonal treatment duration Less than 70 months vs More than 70 months 1 0.001 1 0.001
0.55   0.54  
95% CI [0.39-0.79]   95% CI [0.38-0.77]
Duration of AA treatment Less than 3 months vs More than 3 months 1 <0.001 1 <0.001
0.52   0.55  
95% CI [0.38-0.74]   95% CI [0.39-0.77]